FAQ on Tonix Pharmaceuticals' OASIS Trial for Acute Stress Reaction

What is the OASIS trial evaluating?

The OASIS trial is evaluating TNX-102 SL for its effectiveness in reducing the severity of acute stress reaction (ASR) and preventing the onset of acute stress disorder (ASD) among motor vehicle trauma survivors.

Who is sponsoring the OASIS trial?

The trial is sponsored by the University of North Carolina’s Institute for Trauma Recovery and is backed by a $3 million grant from the U.S. Department of Defense.

How many participants will the OASIS trial enroll?

The trial plans to enroll about 180 motor vehicle trauma survivors at emergency departments across the nation.

What are the expected outcomes of the OASIS trial?

Topline data from the OASIS trial is expected in the second half of 2026, focusing on the reduction of ASR severity and prevention of ASD.

Why is TNX-102 SL considered for this trial?

TNX-102 SL has previously shown improvements in sleep and early PTSD symptoms, which are key factors in mitigating acute stress reaction.

What is the significance of this trial?

This trial addresses the urgent need for effective treatments following traumatic events, benefiting both civilian and military populations.

Where can I find more information about Tonix Pharmaceuticals?

More information about Tonix Pharmaceuticals can be found on their website at www.TonixPharma.com.

What other developments is Tonix Pharmaceuticals working on?

Tonix Pharmaceuticals is also developing TNX-102 SL for fibromyalgia, TNX-4200 for antiviral treatments, and has a CNS portfolio including TNX-1300 for cocaine intoxication, among others.

How can I stay updated on Tonix Pharmaceuticals’ news?

The latest news and updates relating to Tonix Pharmaceuticals (TNXP) are available in the company’s newsroom at https://ibn.fm/TNXP.